DOCSLIB.ORG

IDMA Bulletin 21St June 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IDMA Bulletin 21St June 2021 PRICE LICENSED TO POST WITHOUT PREPAYMENT PER COPY LICENCE NO. MR/Tech/WPP-337/West/2021-23 ` RNI REGN. NO. 18921/1970 25/- REGN NO. MCW/95/2021-23 vol. NO. 52 ISSUE NO. 23 (Pages: 44) 15 TO 21 JUNE 2021 ISSN 0970-6054 WEEKLY PUBLICATION Indian APIs & Formulations for Global Healthcare Implementation of Revised GST for Covid Drugs : IDMA Submission on Draft Guidelines for dealing cases ofIDMA discontinuation representation of Scheduled to Formulations DoP (Page (PageNo. 15) No. 4) ‘Why Phytopharmaceutical Drug Discovery?’ by Dr S S Handa (PageCovid-19: No. 6) On vaccine interval, follow the science (Page No. 23) Advisory: COVID-19 – Amendments/Relaxations/Compliances (PageWatchdog No. 8) tells pharma firms to pass on rate cut Exportbenefits restrictions to consumers on Hydroxychloroquine (Page No. lifted25) (Page No. 19) IDMA Bulletin DoP LII (23)comes 15 to 21 out June with 2021 draft Guidelines for Rs.6,940 crore PLI scheme1 Covid vaccination: The race against time (Page No. 34) to promote domestic production of Bulk Drugs (Page No. 32) IDMA Bulletin LII (23) 15 to 21 June 2021 2 Founder Editor: Vol. No. 52 Issue No. 23 15 to 21 June 2021 Dr A Patani Editor: Dr Gopakumar G Nair Associate Editors: J L Sipahimalani Dr Nagaraj Rao Dr George Patani National President Mahesh H Doshi Immediate Past National President Deepnath Roy Chowdhury Senior Vice-President Dr Viranchi Shah Vice-Presidents: Bharat N. Shah (Western Region) Asheesh Roy (Eastern Region) B K Gupta (Northern Region) T Ravichandiran (Southern Region) Hon General Secretary Dr George Patani Hon Joint Secretaries J Jayaseelan Atul J Shah Hon Treasurer Vasudev Kataria For information contact IDMA Secretariat: (H.O.) Daara B Patel Secretary-General Melvin Rodrigues Sr Manager (Commercial & Administration) C K S Chettiar Asst. Manager (Publications & Administration) Delhi Office: Ashok Kumar Madan Executive Director S Ranganathan Asst Manager (Administration) IDMA STATE BOARDS CHAIRMAN Gujarat State Board : Milan Patel Haryana State Board : P K Gupta Himachal Pradesh & Uttarakhand State Board : R C Juneja Karnataka State Board : S M Mudda Madhya Pradesh State Board : Paresh Chawla Tamil Nadu, Puducherry & Kerala State Board : J Jayaseelan Telangana State Board : Shaik Janimiya West Bengal State Board : Shiv Sagar Tewari A Publication of Indian Drug Manufacturers' Association 102-B, 'A-Wing', Poonam Chambers, Dr. A.B. Road, Worli, Mumbai - 400 018 Tel : 022-2494 4624 / 2497 4308 Fax: 022-2495 0723 e-mail: [email protected]/ [email protected]/ Website: www.idma-assn.org Published on 7th, 14th, 21st and 30th of every month Annual Subscription ` 1000/- (for IDMA members) ` 2000/- (for Government Research/Educational Institutions) ` 4000/- (for non-members) US$ 400 (Overseas) Please send your payment in favour of Indian Drug Manufacturers' Association IDMAOPINIONS Bulletin EXPRESSED LIIXLIV BY TH(23)E AU(38) T15HO RS08 to OF to21 INDIVIDU 14 June OctoberAL AR2021TICLE S2013 3 DO Not NECESSARILY REPRESENT THE OFFICIAL VIEW OF IDMA. Advertisements .................................................................... 2, 4, 33, 38, 39, 42, 43 & 44 IDMA Bulletin Advt. Tariff card ......................................................................................................... 44 ADVERTISEMENT FOR NEW RECRUITMENT ADVERTISEMENT FOR NEW RECRUITMENT ADVERTISEMENTCOMPANYSITUATION FOR INTRODUCTION SNEW VACANT RECRUITMENT COMPANY INTRODUCTION COMPANY INTRODUCTION A reputed Group, engaged in manufactureCOMPANY of Pharmaceutical INTRODUCTION Formulations having Sales of over Rs 200 Cr (Exports constituteA reputed moreGroup, than engaged 50%) and in manufacturecurrently modernising/expanding of Pharmaceutical Formulationsits facilities to having EU GMP Sales Standards of over isRs looking 200 Crfor (Exportssuitable constituteA reputed moreGroup, than engaged 50%) and in manufacturecurrently modernising/expanding of Pharmaceutical Formulationsits facilities to having EU GMP Sales Standards of over isRs looking 200 Crfor (Exportssuitable AFDQGLGDWHV reputed Group, WR ߔOO XSengaged IROORZLQJ in YDFDQFLHV$OOmanufacture of VLWXDWLRQV Pharmaceutical ZLOO UHTXLUH Formulations WKH FDQGLGDWHV having WR Sales VWD\ QHDUof over WKH Rs IDFWRULHV 200 Cr ORFDWHG (Exports LQ FDQGLGDWHVconstitute more WR ߔOO than XS IROORZLQJ50%) and YDFDQFLHV$OOcurrently modernising/expanding VLWXDWLRQV ZLOO UHTXLUH its WKHfacilities FDQGLGDWHV to EU GMP WR VWD\ Standards QHDU WKH is IDFWRULHV looking for ORFDWHG suitable LQ 0DUDWKL+LQGLDQG(QJOLVK/RRNLQJIRU5HVXOWRULHQWHGSHUVRQV more than 50%) and currently modernising/expanding its facilities to EU GMP Standards is looking for suitableڏconstitute0DKDUDVKWUDZLWKLQNPRI0XPEDL/DQJXDJHVNLOOV 0DUDWKL+LQGLDQG(QJOLVK/RRNLQJIRU5HVXOWRULHQWHGSHUVRQV WR ߔOO XS IROORZLQJ YDFDQFLHV$OO VLWXDWLRQV ZLOO UHTXLUH WKH FDQGLGDWHV WR VWD\ QHDU WKH IDFWRULHV ORFDWHG LQڏFDQGLGDWHV0DKDUDVKWUDZLWKLQNPRI0XPEDL/DQJXDJHVNLOOV 0DUDWKL+LQGLDQG(QJOLVK/RRNLQJIRU5HVXOWRULHQWHGSHUVRQVFDQGLGDWHV3URGXFWLRQ7DUJHWVDVZHOODV4XDOLW\RULHQWHGDSSURDFK WR ߔOO XS IROORZLQJ YDFDQFLHV$OO VLWXDWLRQV ZLOO UHTXLUH WKH FDQGLGDWHV WR VWD\ QHDU WKH IDFWRULHV ORFDWHG LQڏ0DKDUDVKWUDZLWKLQNPRI0XPEDL/DQJXDJHVNLOOV 0DUDWKL+LQGLDQG(QJOLVK/RRNLQJIRU5HVXOWRULHQWHGSHUVRQVڏ3URGXFWLRQ7DUJHWVDVZHOODV4XDOLW\RULHQWHGDSSURDFK0DKDUDVKWUDZLWKLQNPRI0XPEDL/DQJXDJHVNLOOV 0DUDWKL+LQGLDQG(QJOLVK/RRNLQJIRU5HVXOWRULHQWHGSHUVRQVڏ3URGXFWLRQ7DUJHWVDVZHOODV4XDOLW\RULHQWHGDSSURDFK0DKDUDVKWUDZLWKLQNPRI0XPEDL/DQJXDJHVNLOOV 3URGXFWLRQ7DUJHWVDVZHOODV4XDOLW\RULHQWHGDSSURDFK1. PRODUCTION MANAGER 1. PRODUCTION MANAGER 'FWECVKQPCN3WCNKſECVKQPU%3KDUP03KDUP1. PRODUCTION MANAGER 'FWECVKQPCN3WCNKſECVKQPU%3KDUP03KDUP1. PRODUCTION MANAGER 'FWECVKQPCN3WCNKſECVKQPU 1. PRODUCTION MANAGER 'FWECVKQPCN3WCNKſECVKQPUAge: 42-46 years %3KDUP03KDUP Age'FWECVKQPCN3WCNKſECVKQPU: 42-46 years %3KDUP03KDUP Age 3RZGHUV LQ D UHSXWHG *03 &HUWLߔHG H[SHULHQFH LQ SURGXFWLRQ RI7DEOHWV&DSVXOHV ڕ \HDUV AgeWork: 42-46 experience years 3RZGHUV LQ D UHSXWHG *03 &HUWLߔHG H[SHULHQFH LQ SURGXFWLRQ RI7DEOHWV&DSVXOHV ڕ \HDUV WorkAge: 42-46 experience years Work&RPSDQ\6KRUWWHUPH[SRVXUHWRSURGXFWGHYHORSPHQWPD\EHDQDVVHW experience 3RZGHUV LQ D UHSXWHG *03 &HUWLߔHG H[SHULHQFH LQ SURGXFWLRQ RI7DEOHWV&DSVXOHV ڕ \HDUVRPSDQ\6KRUWWHUPH[SRVXUHWRSURGXFWGHYHORSPHQWPD\EHDQDVVHWWork experience& 3RZGHUV LQ D UHSXWHG *03 &HUWLߔHG H[SHULHQFH LQ SURGXFWLRQ RI7DEOHWV&DSVXOHV ڕ \HDUVWork experience \H[SHULHQFHDV$VVLVWDQWSURGXFWLRQPDQDJHURU3URGXFWLRQ0DQDJHULQDJRRGVL]HG*03&RPSDQ\SUHIHUDEOڕRPSDQ\6KRUWWHUPH[SRVXUHWRSURGXFWGHYHORSPHQWPD\EHDQDVVHW\HDUV& H[SHULHQFHDV$VVLVWDQWSURGXFWLRQPDQDJHURU3URGXFWLRQ0DQDJHULQDJRRGVL]HG*03&RPSDQ\SUHIHUDEO\&RPSDQ\6KRUWWHUPH[SRVXUHWRSURGXFWGHYHORSPHQWPD\EHDQDVVHWڕLQDQ(8*03RUHTXLYDOHQWXQLW\HDUV \H[SHULHQFHDV$VVLVWDQWSURGXFWLRQPDQDJHURU3URGXFWLRQ0DQDJHULQDJRRGVL]HG*03&RPSDQ\SUHIHUDEOڕLQDQ(8*03RUHTXLYDOHQWXQLW\HDUV \H[SHULHQFHDV$VVLVWDQWSURGXFWLRQPDQDJHURU3URGXFWLRQ0DQDJHULQDJRRGVL]HG*03&RPSDQ\SUHIHUDEOڕ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ſECVKQPU%3KDUP03KDUPZLWK'HJUHHRU'LSORPDLQ$GPLQLVWUDWLRQ0DQDJHPHQW2. FACTORY MANAGER 'FWECVKQPCN3WCNKſECVKQPU%3KDUP03KDUPZLWK'HJUHHRU'LSORPDLQ$GPLQLVWUDWLRQ0DQDJHPHQW2. FACTORY MANAGER 'FWECVKQPCN3WCNKſECVKQPU 2. FACTORY MANAGER 'FWECVKQPCN3WCNKſECVKQPUAge: 45-50 years %3KDUP03KDUPZLWK'HJUHHRU'LSORPDLQ$GPLQLVWUDWLRQ0DQDJHPHQW Age'FWECVKQPCN3WCNKſECVKQPU: 45-50 years %3KDUP03KDUPZLWK'HJUHHRU'LSORPDLQ$GPLQLVWUDWLRQ0DQDJHPHQW Age H[SHULHQFHLQSURGXFWLRQRI)RUPXODWLRQVDWYDULRXVOHYHOVLQDUHSXWHG*03&HUWLߔHGڕ\HDUV AgeWork: 45-50 experience years H[SHULHQFHLQSURGXFWLRQRI)RUPXODWLRQVDWYDULRXVOHYHOVLQDUHSXWHG*03&HUWLߔHGڕ\HDUV WorkAge: 45-50 experience years Work&RPSDQ\([SRVXUHWR5 'PD\EHXVHIXO experience H[SHULHQFHLQSURGXFWLRQRI)RUPXODWLRQVDWYDULRXVOHYHOVLQDUHSXWHG*03&HUWLߔHGڕ\HDUV'PD\EHXVHIXOWork experience RPSDQ\([SRVXUHWR5& H[SHULHQFHLQSURGXFWLRQRI)RUPXODWLRQVDWYDULRXVOHYHOVLQDUHSXWHG*03&HUWLߔHGڕ\HDUVWork experience H[SHULHQFHLQPDQDJHULDOFDSDFLW\LQ3URGXFWLRQPDQDJHPHQWODERXUPDQDJHPHQW*HQHUDODGPLQLVWUDWLRQDQGڕ'PD\EHXVHIXO\HDUV
Load more

Recommended publications
  • Vaccination What Is Vaccination?
    VACCINATION WHAT IS VACCINATION? Vaccination is a simple, safe, and effective way of protecting people against harmful diseases, before they come into contact with them. Makes your immune system stronger. Vaccines train your immune system to create antibodies. SOURCE : World Health Organization Why You Should Get Vaccinated? COVID-19 vaccines are safe and effective. When we get vaccinated, we aren’t just protecting ourselves, but also those around us. Helps to reduce the spread of disease. SOURCE : World Health Organizations Are Vaccines Safe? Vaccination is safe. The benefits of vaccination greatly outweigh the risks, and many more illnesses and deaths would occur without vaccines. SOURCE : World Health Organization Side Effects Of Vaccines Like any medicine, vaccines can cause mild side effects, such as a low- grade fever, or pain or redness at the injection site. Severe or long-lasting side effects are extremely rare. Vaccines are continually monitored for safety, to detect rare adverse events. SOURCE : World Health Organization Types Of Vaccines In India 1. Covaxin 2. Covishield 3. ZyCoV-D 4. Sputnik 5. BBV154 – Intranasal Vaccine 6. Moderna 7. Pfizer SOURCE : Indian Council Of Medical Research Details About Covaxin Covaxin is an inactivated vaccine which means that it is made up of killed coronaviruses, making it safe to be injected into the body. When administered, immune cells can still recognise the dead virus, prompting the immune system to make antibodies against the pandemic virus. The two doses are given four weeks apart. The vaccine can be stored at 2C to 8C. SOURCE : BBC Details About Covishield The vaccine is made from a weakened version of a common cold virus (known as an adenovirus) from chimpanzees.
    [Show full text]
  • 0 January to July 2021
    0 www.journalsofindia.com January to July 2021 SCIENCE & TECH ............................................................................................................................................................... 6 1. REUSABLE LAUNCH VEHICLE TECHNOLOGY DEMONSTRATION PROGRAMME(RLV-TD) ................................................. 6 2. GAGANYAAN MISSION ..................................................................................................................................................... 6 3. MARS ORBITER MISSION (MOM) ..................................................................................................................................... 6 4. CHANDRAYAAN MISSION................................................................................................................................................. 7 5. SOLAR MISSION ............................................................................................................................................................... 8 6. ARTEMIS ACCORD ............................................................................................................................................................ 9 7. NATIONAL MISSION ON INTERDISCIPLINARY CYBER-PHYSICAL SYSTEM (NMICPS) ....................................................... 10 8. SMART ANTI-AIRFIELD WEAPON (SAAW) ...................................................................................................................... 10 9. AQUAPONICS ................................................................................................................................................................
    [Show full text]
  • Molecular Analysis of SARS-Cov-2 Genetic Lineages in Jordan: Tracking the Introduction and Spread of COVID-19 UK Variant of Concern at a Country Level
    pathogens Article Molecular Analysis of SARS-CoV-2 Genetic Lineages in Jordan: Tracking the Introduction and Spread of COVID-19 UK Variant of Concern at a Country Level Malik Sallam 1,2,* and Azmi Mahafzah 1,2 1 Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, The University of Jordan, Amman 11942, Jordan; [email protected] 2 Department of Clinical Laboratories and Forensic Medicine, Jordan University Hospital, Amman 11942, Jordan * Correspondence: [email protected]; Tel.: +962-79-184-5186 Abstract: The rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is manifested by the emergence of an ever-growing pool of genetic lineages. The aim of this study was to analyze the genetic variability of SARS-CoV-2 in Jordan, with a special focus on the UK variant of concern. A total of 579 SARS-CoV-2 sequences collected in Jordan were subjected to maximum likelihood and Bayesian phylogenetic analysis. Genetic lineage assignment was undertaken using the Pango system. Amino acid substitutions were investigated using the Protein Variation Effect Analyzer (PROVEAN) tool. A total of 19 different SARS-CoV-2 genetic lineages were detected, with the most frequent being the first Jordan lineage (B.1.1.312), first detected in August 2020 (n = 424, 73.2%). This was followed by the second Jordan lineage (B.1.36.10), first detected in September 2020 (n = 62, 10.7%), and the UK variant of concern (B.1.1.7; n = 36, 6.2%). In the spike gene region, Citation: Sallam, M.; Mahafzah, A. the molecular signature for B.1.1.312 was the non-synonymous mutation A24432T resulting in a Molecular Analysis of SARS-CoV-2 deleterious amino acid substitution (Q957L), while the molecular signature for B.1.36.10 was the Genetic Lineages in Jordan: Tracking synonymous mutation C22444T.
    [Show full text]
  • REALM Research Briefing: Vaccines, Variants, and Venitlation
    Briefing: Vaccines, Variants, and Ventilation A Briefing on Recent Scientific Literature Focused on SARS-CoV-2 Vaccines and Variants, Plus the Effects of Ventilation on Virus Spread Dates of Search: 01 January 2021 through 05 July 2021 Published: 22 July 2021 This document synthesizes various studies and data; however, the scientific understanding regarding COVID-19 is continuously evolving. This material is being provided for informational purposes only, and readers are encouraged to review federal, state, tribal, territorial, and local guidance. The authors, sponsors, and researchers are not liable for any damages resulting from use, misuse, or reliance upon this information, or any errors or omissions herein. INTRODUCTION Purpose of This Briefing • Access to the latest scientific research is critical as libraries, archives, and museums (LAMs) work to sustain modified operations during the continuing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. • As an emerging event, the SARS-CoV-2 pandemic continually presents new challenges and scientific questions. At present, SARS-CoV-2 vaccines and variants in the US are two critical areas of focus. The effects of ventilation-based interventions on the spread of SARS-CoV-2 are also an interest area for LAMs. This briefing provides key information and results from the latest scientific literature to help inform LAMs making decisions related to these topics. How to Use This Briefing: This briefing is intended to provide timely information about SARS-CoV-2 vaccines, variants, and ventilation to LAMs and their stakeholders. Due to the evolving nature of scientific research on these topics, the information provided here is not intended to be comprehensive or final.
    [Show full text]
  • News in Focus ISHANT CHAUHAN/AP/SHUTTERSTOCK ISHANT People Queue to Refill Oxygen Cylinders for Overwhelmed Medical Facilities in New Delhi
    The world this week News in focus ISHANT CHAUHAN/AP/SHUTTERSTOCK ISHANT People queue to refill oxygen cylinders for overwhelmed medical facilities in New Delhi. CORONAVIRUS VARIANTS ARE SPREADING IN INDIA — WHAT SCIENTISTS KNOW SO FAR Variants including B.1.617 have been linked to India’s surge in infections. Researchers are hurrying to determine how much of a threat they pose. By Gayathri Vaidyanathan detected in India might be more transmissible variants were behind a series of surges in India. and slightly better at evading immunity than Genomic data indicated that B.1.1.7, first iden- cientists are working to understand existing variants. Animal models also hint that tified in the United Kingdom, was dominant in several coronavirus variants now it might be able to cause more severe disease. Delhi and the state of Punjab, and a new variant circulating in India, where a ferocious Researchers want to know whether this variant dubbed B.1.618 was present in West Bengal. second wave of COVID-19 has devas- and others might be driving the second wave B.1.617 was dominant in Maharashtra. tated the nation and caught authori- and what kind of danger they pose globally. But, since then, B.1.617 has overtaken B.1.618 Sties unawares. The country recorded nearly In just a few weeks, the B.1.617 variant has in West Bengal, has become the leading vari- 400,000 new infections on 9 May, taking its become the dominant strain across India and ant in many states, and is increasing rapidly total to more than 22 million (see ‘Surging has spread to about 40 nations, including the in Delhi.
    [Show full text]
  • Development of New Vaccines for Tuberculosis
    August 21, 1998 / Vol. 47 / No. RR-13 TM Recommendations and Reports Development of New Vaccines for Tuberculosis Recommendations of the Advisory Council for the Elimination of Tuberculosis (ACET) U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention (CDC) Atlanta, Georgia 30333 The MMWR series of publications is published by the Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Hu- man Services, Atlanta, GA 30333. SUGGESTED CITATION Centers for Disease Control and Prevention. Development of new vaccines for tu- berculosis: recommendations of the Advisory Council for the Elimination of Tuberculosis (ACET). MMWR 1998;47(No. RR-13):[inclusive page numbers]. Centers for Disease Control and Prevention................................ Claire V. Broome, M.D. Acting Director The material in this report was prepared for publication by National Center for HIV, STD, and TB Prevention ......... Helene D. Gayle, M.D., M.P.H. Director Division of Tuberculosis Elimination ...................................Kenneth G. Castro, M.D. Director The production of this report as an MMWR serial publication was coordinated in Epidemiology Program Office............................................Barbara R. Holloway, M.P.H. Acting Director Office of Scientific and Health Communications ......................John W. Ward, M.D. Director Editor, MMWR Series Recommendations and Reports................................... Suzanne M. Hewitt, M.P.A. Managing Editor Amanda Crowell Project Editor Morie M. Higgins Visual Information Specialist Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services. Copies can be purchased from Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402-9325.
    [Show full text]
  • Editorial 10.5005/Ijmb-24-3-Iv
    Editorial 10.5005/ijmb-24-3-iv COVID-19 Vaccines: Lets Go for It SARS CoV-2, also christened as COVID-19 is an acute respiratory illness caused by a novel coronavirus which originated from Wuhan China in 2019 and within a short span affected virtually each and every country around the globe, throwing healthcare preparedness and economy out of gear. The world was faced with a pandemic leading to overcrowded hospitals and overflowing mortuaries. Lockdowns imposed in countries jeopardized routine life never to normalize again. India has been among the top three countries with the maximum number of afflicted people. Thankfully , our statistics with respect to mortality is better as compared to the western world. The last year 2020 was completely COVIDISED if we may say so. The world economy is in doldrums and the health infrastructure is overstretched and fatigued. Everytime we feel that the disease is under control, the virus cleverly mutates to become more infective and develops increased ability to escape the immune surveillance. Efforts to develop a vaccine against this scourge were initiated at a war footing across the globe. A number of vaccines were approved for emergency use since the scientific committee didn’t have the time to wait further. In India, two vaccines- Covaxin and Covishield have been approved by the Government of India for mass vaccination. The mammoth program was initiated with first preference for the healthcare workers and frontline warriors. In the next phases, elderly population followed by the rest of the population in a phased manner was planned. It is really incredible and praiseworthy about the immaculate planning and implementation of the initiative in our country where the diversity is both a boon as well as bane.
    [Show full text]
  • State of the World's Vaccines and Immunization
    State of the world’s vaccines and immunization Third edition Suggested citation: WHO, UNICEF, World Bank. State of the world’s vaccines and immunization, 3rd ed. Geneva, World Health Organization, 2009. This book is dedicated to all those individuals who work tirelessly to improve and save lives through vaccines and immunization. WHO Library Cataloguing-in-Publication Data State of the world's vaccines and immunization. -- 3rd ed. 1.Immunization programs 2.Immunization 3.Vaccines 4.Biomedical research 5.Child 6.Infant 7.Interinstitutional relations 8.International cooperation 9.Developing countries I.World Health Organization. ISBN 978 92 4 156386 4 (NLM classification: WA 110) © World Health Organization 2009 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention, or photographic illustration, of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Remdesivir: First Approval
    Drugs https://doi.org/10.1007/s40265-020-01378-w ADISINSIGHT REPORT Remdesivir: First Approval Yvette N. Lamb1 © Springer Nature Switzerland AG 2020 Abstract The antiviral agent remdesivir (Veklury ®; Gilead Sciences), nucleotide analogue prodrug, has broad-spectrum activity against viruses from several families. Having demonstrated potent antiviral activity against coronaviruses in preclini- cal studies, remdesivir emerged as a candidate drug for the treatment of the novel coronavirus disease 2019 (COVID- 19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, during the current global pandemic. Phase III evaluation of remdesivir in the treatment of COVID-19 commenced in early 2020 and has thus far yielded promising results. In late May 2020, Taiwan conditionally approved the use of remdesivir in patients with severe COVID-19. This was followed by a rapid succession of conditional approvals in various countries/regions including the EU and Canada. Preceding these conditional approvals, an emergency use authorization for remdesivir had been granted in the USA (on 1 May 2020) and a special approval for emergency use was granted in Japan (on 7 May 2020). This article summarizes the milestones in the development of remdesivir leading to its first conditional approval for the treatment of COVID-19. Remdesivir (Veklury®): Key points 1 Introduction A nucleotide analogue prodrug is being developed by Remdesivir (Veklury®; Gilead Sciences), a prodrug of Gilead Sciences for the treatment of COVID-19 an adenosine nucleotide analogue, is an antiviral agent with broad-spectrum activity against viruses from several Received its frst emergency use authorization on 1 May families [1–4].
    [Show full text]
  • Bjpworker Shot PM Modi Chairs CCS Meeting to Dead by Militants in Cases, One Death Review Situation in Afghanistan JAMMU RISING Gus) in the Union Territory
    JAMMU, WEDNESDAY, AUGUST 18, 2021 JAMMU RISING NEWS P-3 NEWS P-5 NEWS P-12 NATIONAL P-8 SPORT P-7 Advisor 9 Doda youth 36 Keralites T20 World Cup: Bhatnagar get Ramban Admin felicitates DPO stranded in Kabul conducts commercial ICC releases with ‘EX- seek urgent help to vehicles schedule, India- extensive CELLENT return home; CM tour of under Pakistan match CIVILSER- reaches out to Jammu MUMKIN VICES AWARD’ on October 24 city scheme Centre Price: Rs.1 | Page 12 | Vol. No.: 11 | Issue No: 191 Postal Registration No. JK-458/16-18 epaper.dailyjammurising.in RNI No: JKENG/2011/40494 BRIEF NEWS J&K reports 83 COVID-19 BJPworker shot PM Modi chairs CCS meeting to dead by militants in cases, one death review situation in Afghanistan JAMMU RISING gus) in the union territory. The Bulletin also informs J&K’s Kulgam JAMMU, AUG 17 The Government on Tues- that no new confirmed case ABJP worker was shot dead NEW DELHI,AUG 17 tional status of Kabul airport. Jammu and Kashmir day informed that 83 new of Mucormycosis has been by militants in Brazloo area of Prime Minister Narendra This has been discussed at recorded 83 fresh COVID- positive cases of novel reported today, thus the total South Kashmir’s Kulgam dis- Modi chaired a meeting of high levels with our partners, 19 cases and one fatality on Corona virus (COVID-19), number of confirmed cases trict today. the Cabinet Committee on including by EAM with the Tuesday, pushing the union 38 from Jammu division and remains 42 in the UT of Militants fired upon BJP In- Security on Tuesday to re- US Secretary of State.
    [Show full text]
  • (COVID-19), Chemical Structure, Therapeutics, Drugs and Vaccines
    Review Volume 12, Issue 1, 2022, 547 - 566 https://doi.org/10.33263/BRIAC121.547566 Coronavirus Disease (COVID-19), Chemical Structure, Therapeutics, Drugs and Vaccines Vesen Atiroğlu 1,2 , Atheer Atiroğlu 1,2 , Münteha Özsoy 2,3 , Mahmut Özacar 2,3,* 1 Sakarya University, Biomedical, Magnetic and Semiconductor Materials Application and Research Center (BIMAS-RC), 54187, Sakarya, Turkey 2 Sakarya University, Biomaterials, Energy, Photocatalysis, Enzyme Technology, Nano & Advanced Materials, Additive Manufacturing, Environmental Applications, and Sustainability Research & Development Group (BIOEℕAMS R&D Group), 54187 Sakarya, Turkey 3 Sakarya University, Science & Arts Faculty, Department of Chemistry, 54187, Sakarya, Turkey * Correspondence: [email protected] (M.O.); Scopus Author ID 6603796256 Received: 27.02.2021; Revised: 3.04.2021; Accepted: 6.04.2021; Published: 20.04.2021 Abstract: Biochemistry has the main role to play in understanding the structure of viral to develop techniques and materials used by clinicians, virologists, and researchers, as well as isolation of therapies and vaccines. Biochemistry helps to understand the molecules that manage virus structure and function can accelerate discovering means to treat and avoid infectious disease. The significant contributions of biochemistry are providing to understanding and monitoring the spread of coronaviruses. COVID-19 is a novel type of coronavirus influence humans and was recognized in 2019. The terms severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), 2019 novel coronavirus, and COVID-19 mention the same virus. All present medication choices are based on experience with MERS, SARS, and other new influenza viruses. Thus, it is essential to understand the virus structure and its clinical features to respond to the COVID-19 outbreak.
    [Show full text]
  • Asia COVID-19 & Vaccine Tracker
    9 July 2021 Free to View Asia COVID-19 & Vaccine Tracker Economics - Asia Tougher restrictions As COVID-19 cases continue to surge across Asia, more Yun Liu authorities have re-imposed restrictions or even lockdowns Economist The Hongkong and Shanghai Banking Corporation Limited But this has increased the urgency to ramp up vaccine Frederic Neumann procurement and roll-out in the region Co-Head of Asian Economics Research The Hongkong and Shanghai Banking Corporation Limited Some economies have started pilot programmes to revive tourism, but a full re-opening may take a long time Maitreyi Das Associate Bangalore Déjà vu No end in sight just yet. The Delta variant is causing daily new COVID-19 cases to surge to new record highs across Asia, prompting more governments to re-impose tougher restrictions. This is particularly evident in ASEAN, where cases in Indonesia and Vietnam have been rising sharply. The former has extended its tightening measures throughout the country until 20 July, while the latter will impose a strict lockdown in Ho Chi Minh City (HCMC) from 9 July for 15 days. Meanwhile, just two weeks before the Tokyo Olympics, Japan is set to declare its fourth state of emergency in Tokyo from 12 July to 20 August, raising the possibility of no spectators attending the games. Meanwhile, Singapore is the only country that has decided to ease its social restrictions from 12 July, as new cases remain low. Urgency on vaccination The recent outbreaks in the region has alerted the authorities that the key to exiting the pandemic is to accelerate vaccine procurement and roll-out.
    [Show full text]